RTP Mobile Logo
Submitted by web@researchtop... on Tue, 03/17/2020 - 13:55

Interview with Daniel A Pollyea, MD, MS

Topic 1: Choice of first-line therapy for acute myeloid leukemia (AML); selection of patients who are fit for intensive chemotherapy
Topic 2: Perspective on the choice of hypomethylating agent (HMA) to combine with venetoclax
Topic 3: Clinical implications of the Phase III QUAZAR AML-001 study assessing maintenance CC-486 for patients with AML in first remission
Topic 4: Potential implications of combining CC-486 with venetoclax for AML
Topic 5: Biologic rationale for the synergistic effect of venetoclax with an HMA or low-dose cytarabine for patients with AML
Topic 6: Identifying nonresponders to venetoclax-based combination therapy; managing the monocytic (FABM5) subgroup of AML
Topic 7: Rationale for combining venetoclax with azacitidine; optimal duration of HMA therapy
Topic 8: Monitoring bone marrow counts in patients with AML receiving venetoclax-based therapy; role of dose interruptions in managing cytopenias
Topic 9: Effect of venetoclax-based combinations on extramedullary disease
Topic 10: Strategies to mitigate tumor lysis syndrome associated with venetoclax-based therapy
Topic 11: Perspective on the use of prophylaxis to reduce the risk of infections associated with venetoclax
Topic 12: Recommendations for hospitalization of patients with AML receiving venetoclax-based therapies
Topic 13: Use of venetoclax/HMA therapy in patients with AML and high white blood cell counts
Topic 14: Benefit with the addition of venetoclax to an HMA for patients with AML
Topic 15: Outcomes for patients with AML experiencing disease relapse on venetoclax with an HMA; mechanisms of resistance to the venetoclax and HMA combination
Topic 16: Potential for venetoclax-based combinations for patients with AML eligible for intensive induction chemotherapy
Topic 17: Case: A woman in her mid-30s with high-risk AML who is ineligible for induction chemotherapy achieves a complete response with venetoclax and azacitidine
Topic 18: Perspective on the potential use of venetoclax/HMA prior to transplant
Topic 19: Therapeutic approach for older patients with AML harboring FLT3 and IDH mutations
Topic 20: Challenges associated with the use of venetoclax-based combinations
Topic 21: Quality-of-life impact and tolerability of venetoclax/HMA therapy
Topic 22: Emerging options for patients with AML harboring p53 mutations
Topic 23: Rationale for the investigation of the novel, first-in-class small molecule APR-246 in combination with azacitidine for patients with AML with TP53 mutations
Topic 24: Activity and tolerability of APR-246 in AML

Interview with Richard M Stone, MD

Topic 1: Design and results of the QUAZAR AML-001 maintenance trial assessing CC-486 versus placebo for patients with AML in first remission
Topic 2: Mechanism of action of azacitidine in AML
Topic 3: Preclinical data on the use of anti-inflammatory agents for clonal hematopoiesis of indeterminate potential (CHIP)
Topic 4: Ongoing investigations of anti-CD47 antibodies, antibody-drug conjugates and immune checkpoint inhibitors for AML
Topic 5: Clinical relevance of CHIP mutations
Topic 6: Pathophysiology of CHIP mutations and cardiovascular disease
Topic 7: Composition of CPX-351; advantages and disadvantages in the management of AML
Topic 8: Efficacy and safety of CPX-351 for secondary AML; patient selection for treatment with CPX-351
Topic 9: Investigation of venetoclax-based combination strategies in AML
Topic 10: Factors determining eligibility for intensive chemotherapy for older and younger patients with AML
Topic 11: Counseling patients on potential outcomes of intensive chemotherapy for AML
Topic 12: Duration of therapy with an HMA and venetoclax for patients with AML
Topic 13: Genetic alterations in AML; incidence and biology of FLT3 mutations
Topic 14: Clinical presentation of patients with AML with FLT3 mutations; activity of the FLT3 inhibitors gilteritinib and midostaurin
Topic 15: Role of FLT3 inhibitors as a bridge to transplant and in the post-transplant setting
Topic 16: Tolerability of FLT3 inhibitors for patients with AML and choice of agent in the post-transplant maintenance setting
Topic 17: Evidence with and ongoing investigation of the FLT3 inhibitor quizartinib in patients with AML with a FLT3 mutation
Topic 18: Incidence of IDH mutations in AML; treatment for AML with IDH1 and IDH2 mutations
Topic 19: Differentiation syndrome with IDH inhibitors: Incidence, presentation and management
Topic 20: Treatment options for patients with AML harboring IDH or FLT3 mutations who are unfit for intensive chemotherapy
Topic 21: Future developments in the management of AML
Topic 22: Long-term outcomes with HMA and venetoclax in AML
 
FACULTY
 
Daniel A Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Robert H Allen, MD Chair
in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado
 
Richard M Stone, MD
Director
Translational Research, Leukemia Division
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida